Status:
TERMINATED
RCT of MBCT vs HEP for Late-Life Depression
Lead Sponsor:
Lady Davis Institute
Conditions:
Depression in Old Age
Quality of Life
Eligibility:
All Genders
60-100 years
Phase:
NA
Brief Summary
Study Design \& Recruitment: Phase III randomized controlled trial (RCT) with 100-110 patients. Participants \>60 years old, with symptoms of late-life depression (LLD; MADRS score\>=10), excluding de...
Detailed Description
Late life depression (LLD) affects 5 million American seniors yearly with $1.81 billion in direct health-care costs. Biomarkers of LLD have consistently been linked to elevated dementia risk. Mindfuln...
Eligibility Criteria
Inclusion
- MADRS score ≥ 10 (experiencing symptoms of moderate/severe depression) at baseline
- Ability to provide informed consent (shown as to be able to explain back to the research assistant the purpose of the study as well as voluntary participation, rights, time commitments, etc.)
- participants who have access to internet and basic digital skills to use their computer/tablet
- willing and able to attend ≥75% of MBCT or HEP sessions
- adequate understanding of English or French
- ability to sit for 90 minutes without discomfort
- willing to inform if any change is made to their psychotropic medications and dosage for the first 8 weeks of the study
Exclusion
- cognitive deficits at baseline, as defined by MoCA score \<19
- diagnosis of post-traumatic stress disorder, bipolar I or II disorder, primary psychotic disorder (e.g. schizophrenia, schizoaffective disorder), and/or severe personality disorder interfering with ability to function in a group setting intervention on a regular basis
- substance abuse within the past 6 months
- high suicide risk (e.g., active suicidal ideation and/or recent intent or plan)
- significant visual or hearing impairment
- significant impairments in fine motor skills
- any medical illnesses that could prevent the participant from engaging in the intervention
- history of psychiatric hospitalization in the last 3 months
Key Trial Info
Start Date :
October 1 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2025
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05366088
Start Date
October 1 2023
End Date
May 1 2025
Last Update
June 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lady Davis Institute
Montreal, Quebec, Canada, H3T 1E1